Protalix and Chiesi Plan Q1 2020 Filing For Accelerated FDA Approval

 
• By Scrip Team

The companies plan to use surrogate endpoint data to win approval to challenge Sanofi and Shire for the Fabry disease market.

Arrow flying to target with radial motion blur
Hoping For A Direct Shot

More from New Products

More from Scrip